Quick Answer
Immix Biopharma, Inc. reported Net Income of -$29.44 million for fiscal year 2025.
Immix Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$29.44M | -36.2% |
| 2024 | -$21.61M | -40.1% |
| 2023 | -$15.43M | -87.4% |
| 2022 | -$8.23M | +66.2% |
| 2021 | -$24.38M | -2024.3% |
| 2020 | -$1.15M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.59M | -6.1% | -14.5% |
| June 30, 2025 | -$6.62M | -50.8% | -45.8% |
| March 31, 2025 | -$4.54M | +13.6% | +36.5% |
| September 30, 2024 | -$7.15M | -67.0% | -62.7% |
| June 30, 2024 | -$4.39M | -22.8% | +16.5% |
| March 31, 2024 | -$5.26M | -112.1% | -22.9% |
| September 30, 2023 | -$4.28M | -178.9% | -19.7% |
| June 30, 2023 | -$3.58M | -128.8% | -44.2% |
- Immix Biopharma, Inc. showed a decrease of -36.2% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Immix Biopharma, Inc.’s net income has declined by 2464.6% (from -$1.15 million to -$29.44 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: